Better than expected revenues will push US firm founded in 2010 into profit for first time
Moderna expects to rake in $18.4bn (£13bn) of sales from its coronavirus vaccine this year, marking a huge turnaround in the fortunes of the US biotech firm.
The expected revenue is far higher than the $11.2bn predicted by analysts, and exceeds the $15bn in sales that its US rival Pfizer expects for the Covid-19 vaccine that it developed with Germany’s BioNTech.
